S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
NASDAQ:GH

Guardant Health - GH Stock Forecast, Price & News

$26.55
+0.60 (+2.31%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$25.80
$26.98
50-Day Range
$25.01
$33.76
52-Week Range
$24.20
$77.72
Volume
3.50 million shs
Average Volume
1.97 million shs
Market Capitalization
$2.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.64

Guardant Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
117.1% Upside
$57.64 Price Target
Short Interest
Bearish
7.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.78mentions of Guardant Health in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$1.25 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($4.50) to ($3.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

59th out of 988 stocks

Medical Laboratories Industry

3rd out of 24 stocks


GH stock logo

About Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Guardant Health (NASDAQ:GH) Shares Gap Down to $28.88
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Earnings Outlook For Guardant Health
Goldman Sachs Keeps Their Buy Rating on Guardant Health (GH)
GH.OQ - | Stock Price & Latest News | Reuters
See More Headlines
Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Company Calendar

Last Earnings
11/04/2021
Today
3/21/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
1,793
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$57.64
High Stock Price Forecast
$88.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+117.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$-654,590,000.00
Net Margins
-145.61%
Pretax Margin
-145.36%

Debt

Sales & Book Value

Annual Sales
$449.54 million
Book Value
$0.59 per share

Miscellaneous

Free Float
96,607,000
Market Cap
$2.73 billion
Optionable
Not Optionable
Beta
0.86

Key Executives

  • Helmy EltoukhyHelmy Eltoukhy
    Chairman & Co-Chief Executive Officer
  • AmirAli H. TalasazAmirAli H. Talasaz
    Co-Chief Executive Officer & Director
  • Andrew Ament
    Senior Vice President-Operations
  • Michael Bell
    Chief Financial & Accounting Officer
  • Darya Chudova
    Senior Vice President-Technology













GH Stock - Frequently Asked Questions

Should I buy or sell Guardant Health stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GH shares.
View GH analyst ratings
or view top-rated stocks.

What is Guardant Health's stock price forecast for 2023?

13 equities research analysts have issued 12 month price targets for Guardant Health's shares. Their GH share price forecasts range from $33.00 to $88.00. On average, they predict the company's share price to reach $57.64 in the next year. This suggests a possible upside of 120.0% from the stock's current price.
View analysts price targets for GH
or view top-rated stocks among Wall Street analysts.

How have GH shares performed in 2023?

Guardant Health's stock was trading at $27.20 at the start of the year. Since then, GH shares have decreased by 3.7% and is now trading at $26.20.
View the best growth stocks for 2023 here
.

Are investors shorting Guardant Health?

Guardant Health saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 7,000,000 shares, an increase of 13.1% from the February 13th total of 6,190,000 shares. Based on an average trading volume of 2,060,000 shares, the days-to-cover ratio is currently 3.4 days. Approximately 7.2% of the company's stock are sold short.
View Guardant Health's Short Interest
.

When is Guardant Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our GH earnings forecast
.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) issued its earnings results on Thursday, November, 4th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $0.16. The business had revenue of $94.80 million for the quarter, compared to the consensus estimate of $92.59 million. Guardant Health had a negative trailing twelve-month return on equity of 242.65% and a negative net margin of 145.61%. The firm's revenue was up 26.9% compared to the same quarter last year. During the same period last year, the company earned ($0.78) EPS.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health issued an update on its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $525.00 million-$540.00 million, compared to the consensus revenue estimate of $554.00 million.

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Clearbridge Investments LLC (2.53%), Alliancebernstein L.P. (2.46%), Price T Rowe Associates Inc. MD (1.66%), Geode Capital Management LLC (1.39%), Voya Investment Management LLC (1.34%) and Norges Bank (0.77%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Michael J Wiley, Samir Kaul, Stanley J Meresman and Stanley J Meresman.
View institutional ownership trends
.

How do I buy shares of Guardant Health?

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $26.20.

How much money does Guardant Health make?

Guardant Health (NASDAQ:GH) has a market capitalization of $2.69 billion and generates $449.54 million in revenue each year. The company earns $-654,590,000.00 in net income (profit) each year or ($6.40) on an earnings per share basis.

How many employees does Guardant Health have?

The company employs 1,793 workers across the globe.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for the company is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at investors@guardanthealth.com, or via fax at 888-974-4258.

This page (NASDAQ:GH) was last updated on 3/21/2023 by MarketBeat.com Staff